TRANSCUTANEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING A STEROID HORMONE

• US 20100292199A1
• Filed: 12/04/2008
• Published: 11/18/2010
• Est. Priority Date: 12/14/2007
• Status: Abandoned Application

• Current Assignee: Pierre Fabre Medicament (Fondation Pierre Fabre)
• Original Assignee: Pierre Fabre Medicament (Fondation Pierre Fabre)
• Inventors: Leverd, Elie, Bougaret, Joël
• Application Number:
  US12/812,727
• Publication Number:
  US 20100292199A1
• Time in Patent Office: Days
• US Class Current: 514/178
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: G01S 15/8929 using a three-dimensional transducer configuration
• CPC Class Codes: G01S 7/52047 for elimination of side lobes or of grating lobes; for increasing resolving power

Abstract

The present invention concerns aqueous-alcoholic, single-phase transcutaneous pharmaceutical compositions with an amount of alcohol of greater than 30% containing a steroid hormone combined with at least one penetrating agent selected from propylene glycol fatty acid esters, terpene derivatives, and mixtures thereof.

Claims

1. Transcutaneous pharmaceutical compositions of monophasic hydroalcoholic type with a quantity of alcohol greater than 30% and containing a steroidal hormone linked to at least one fatty acid ester and propylene glycol as penetration agent.

2. The transcutaneous pharmaceutical compositions as claimed in claim 1, characterised in that they contain N, N-di-ethyl-m-toluamide or DEET as apolar solvent soluble in the hydroalcoholic phase, with a concentration varying from 0.1 to 0.5% (m/m) of the composition.

3. The transcutaneous pharmaceutical compositions as claimed in any one of claims 1 and 2, characterised in that they are in the form of gels or solutions containing testosterone as steroidal hormone, with a concentration varying from 0.1% to 5% (m/m) of the composition.

4. The transcutaneous pharmaceutical compositions as claimed in any one of claims 1 to 3, characterised in that they contain at least one gelling agent, such as a carbomer.

5. The transcutaneous pharmaceutical compositions as claimed in any one of claims 1 to 4, characterised in that the concentration of the fatty acid ester and propylene glycol varies from 0.5% to 10% (m/m) of the composition.

6. The transcutaneous pharmaceutical compositions as claimed in any one of claims 1 to 5, characterised in that they contain 2.5% (m/m) of propylene glycol monolaurate.

7. The transcutaneous pharmaceutical compositions as claimed in any one of claims 1 to 6, characterised in that they contain 5% (m/m) of propylene glycol monocaprylate.

8. The transcutaneous pharmaceutical compositions as claimed in any one of claims 1 to 7, characterised in that they contain a mixture, preferably equiweighted, of propylene glycol monolaurate and propylene glycol monocaprylate.

9. The transcutaneous pharmaceutical compositions as claimed in any one of claims 1 to 8, characterised in that they contain a terpenic derivative as additional penetration agent with a concentration varying from 0.5% to 10% (m/m) of the composition.

10. The transcutaneous pharmaceutical compositions as claimed in claim 9, characterised in that they contain 2.5% (m/m) of levomenthol.